218 related articles for article (PubMed ID: 20180063)
1. [Systemic treatment of metastatic prostate cancer].
Wörmann B; Wolff JM
Urologe A; 2010 Feb; 49(2):221-7. PubMed ID: 20180063
[TBL] [Abstract][Full Text] [Related]
2. [Androgen deprivation for advanced prostate cancer].
Heidenreich A; Pfister D; Ohlmann CH; Engelmann UH
Urologe A; 2008 Mar; 47(3):270-83. PubMed ID: 18273599
[TBL] [Abstract][Full Text] [Related]
3. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of prostate cancer].
Romics I
Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076
[No Abstract] [Full Text] [Related]
6. Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer.
Price N
Clin Prostate Cancer; 2004 Sep; 3(2):77-9. PubMed ID: 15479488
[No Abstract] [Full Text] [Related]
7. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
Rübben H
Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
[TBL] [Abstract][Full Text] [Related]
8. Preservation of bone health in prostate cancer.
Lattouf JB; Saad F
Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
[TBL] [Abstract][Full Text] [Related]
9. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
Bankhead C
J Natl Cancer Inst; 2003 Sep; 95(17):1273-4. PubMed ID: 12953081
[No Abstract] [Full Text] [Related]
11. Choice of first-line treatment for metastatic prostate cancer.
Prescrire Int; 2013 Feb; 22(135):51. PubMed ID: 23444511
[No Abstract] [Full Text] [Related]
12. Androgen suppression strategies for prostate cancer: is there an ideal approach?
Ismail M; Ferroni M; Gomella LG
Curr Urol Rep; 2011 Jun; 12(3):188-96. PubMed ID: 21384154
[TBL] [Abstract][Full Text] [Related]
13. The benefits of early androgen blockade.
Maroni PD; Crawford ED
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
[TBL] [Abstract][Full Text] [Related]
14. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
15. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
16. Current topics and perspectives relating to hormone therapy for prostate cancer.
Suzuki H; Kamiya N; Imamoto T; Kawamura K; Yano M; Takano M; Utsumi T; Naya Y; Ichikawa T
Int J Clin Oncol; 2008 Oct; 13(5):401-10. PubMed ID: 18946750
[TBL] [Abstract][Full Text] [Related]
17. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
18. [Current treatment of locally advanced and metastatic prostate cancer].
Ponholzer A; Steinbacher F; Madersbacher S; Schramek P
Wien Med Wochenschr; 2011 Aug; 161(15-16):377-81. PubMed ID: 21953428
[TBL] [Abstract][Full Text] [Related]
19. [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
Uphoff J; Woziwodzki J; Schattka SO; Kollias A
Aktuelle Urol; 2008 Sep; 39(5):373-7. PubMed ID: 18798127
[TBL] [Abstract][Full Text] [Related]
20. The changing pattern of management for hormone-refractory, metastatic prostate cancer.
James ND; Bloomfield D; Luscombe C
Prostate Cancer Prostatic Dis; 2006; 9(3):221-9. PubMed ID: 16801939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
